QTRXBullishQuanterix exclusive distribution deal with Sherman Abrams Laboratorynews
Medium materiality4/10
Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory
Nov 16, 2026, 1:41 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The deal expands regional commercial access to LucentAD, creating a clearer revenue channel for Quanterix’s diagnostic test if referral volumes scale; the magnitude depends on physician adoption and testing volume.
AI summary
What happened, with direct paths to the underlying reporting
Quanterix signed an exclusive distribution agreement with Sherman Abrams Laboratory to offer LucentAD® Complete blood-based Alzheimer’s testing across New Jersey and the surrounding Metro NY/NJ region.
Quanterix announced an exclusive distribution agreement with Sherman Abrams Laboratory to bring its LucentAD® Complete blood tests to patients across New Jersey and the surrounding area.
Under the exclusive arrangement, Sherman Abrams will offer LucentAD Complete testing to its network of referring physicians throughout the Metro NY/NJ region to expand patient access.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
- Quanterix reported a quarterly loss of $0.26 per share, beating the consensus estimate of a loss of $0.33. - The company posted revenues of $32.07 million, surpassing the consen…